ZNTL Zentalis Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1725160 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.8%
TTM net income YoY16.7%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-615.2%
Net margin-555.8%
FCF margin-498.8%
EBITDA margin-611.8%
Returns
ROE-49.2%
ROA-38.4%
ROIC (approx.)-49.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets22.7%
Debt / equity0.00x
Current ratio7.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $67.42M |
| R&D expense | $107.30M | $167.77M |
| SG&A expense | $37.72M | $87.11M |
| Operating income | -$152.81M | -$191.19M |
| Pretax income | -$136.62M | -$165.69M |
| Income tax | $442,000 | $177,000 |
| Net income | -$137.06M | -$165.84M |
| EBITDA | -$152.07M | -$189.91M |
| EPS (basic) | -1.91 | -2.33 |
| EPS (diluted) | -1.91 | -2.33 |
| Weighted avg. shares (diluted) | 71.87M | 71.08M |
| Balance sheet | ||
| Cash & equivalents | $35.99M | $36.53M |
| Short-term investments | $209.90M | $318.01M |
| Receivables | $0 | $5.00M |
| Current assets | $253.19M | $386.07M |
| PP&E, net | $2.77M | $4.70M |
| Goodwill | — | $0 |
| Total assets | $288.97M | $430.34M |
| Current liabilities | $36.56M | $52.73M |
| Total liabilities | $72.76M | $93.15M |
| Shareholders' equity | $216.20M | $337.19M |
| Shares outstanding | 69.09M | 71.28M |
| Cash flow statement | ||
| Operating cash flow | -$125.25M | -$170.86M |
| Capital expenditure | $0 | $221,000 |
| Free cash flow | -$125.25M | -$171.08M |
| Investing cash flow | $131.62M | $176.56M |
| Financing cash flow | -$4.28M | $108,000 |
| Depreciation & amortization | $739,000 | $1.29M |
| Stock-based compensation | $20.72M | $67.27M |
| Share buybacks | $9.98M | $0 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.